Gilead Stock News

The drugmaker said that a network of little-known drug suppliers and distributors sold illicit and potentially dangerous fake versions of its HIV medicines that ended up in pharmacies and in the hands of patients.

GlaxoSmithKline PLC ( GSK , Financial), Pfizer Inc. ( PFE , Financial) and Johnson & Johnson ( JNJ , Financial) should all know about mid-year if the shots they're developing for a common and potentia

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2021 financial results will be released on Tuesday, Februar

Gilead Sciences Inc (NASDAQ: GILD ) recently notified the FDA of its decision to voluntarily withdraw the use of Zydelig for two types of blood cancer, including follicular lymphoma (FL) and small lymphocytic leukemia (SLL). In 2014, the FDA granted accelerated approval to treat relapsed follicular B-cell non-Hodgkin lymphoma and relapsed small lymphocytic leukemia, … Full story available on Benzinga.com

Companies with growing dividends can give you a buffer that prevents you from selling stocks in bad times.

Gilead Sciences Inc (NASDAQ: GILD) recently notified the FDA of its decision to voluntarily withdraw the use of Zydelig for two types of blood cancer, including follicular lymphoma (FL) and small l

These drugmakers should have no problems keeping the dividends flowing -- and growing.

Tekla Healthcare Investors: Understanding The Mechanics Of Its 8.5% Yield

These potential corporate combinations would make a lot of sense.

DUBLIN , Jan. 12, 2022 /PRNewswire/ -- The "Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2021" report has been added to ResearchAndMarkets.com''s offering. The Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014- 2021 report provides comprehensive access to available deals and contract documents for over 2,900 clinical stage deals. The report provides a detailed understanding and analysis of how and why companies enter clinical stage partnering deals and provides details of the latest clinical agreements announced in the healthcare sector. Understanding the flexibility of a prospective partner''s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

Following are excerpts from CNBC interviews with Gilead Sciences, Inc. (NASDAQ:GILD) Chairman & CEO Daniel ODay and Novavax, Inc. (NASDAQ:NVAX) President & CEO Stanley Erck on CNBCs Squawk on the Street (M-F 9AM 11AM ET) today, Monday, January 10th. Following is a link to video on CNBC.com: Q4 2021 hedge fund letters, conferences and []

Gilead Sciences, Inc.'s (GILD) CEO Daniel O'Day on JPMorgan 40th Annual Healthcare Conference (Transcript)

Gilead Sciences (pembrolizumab) is partnering with Merck to examine a combination of the former''s Trodelvy with the latter''s Keytruda (pembrolizumab) for first-line NSCLC.